BIO Deutschland at the Industrial Health Care Industry Expert Forum with Karl Lauterbach

Foto: (v.l.): Verena Hubertz (MdB), Viola Bronsema, Gabriele Katzmarek (MdB), Karl Lauterbach (BMG), Beate Bockelt (Betriebsrat Sanofi-Aventis Deutschland GmbH), Daniel Steiners (Roche Pharma AG), Francesco Grioli (IG BCE), Matthias Mieves (MdB) © Andreas Amann

Foto: (v.l.): Verena Hubertz (MdB), Viola Bronsema, Gabriele Katzmarek (MdB), Karl Lauterbach (BMG), Beate Bockelt (Betriebsrat Sanofi-Aventis Deutschland GmbH), Daniel Steiners (Roche Pharma AG), Francesco Grioli (IG BCE), Matthias Mieves (MdB) © Andreas Amann

BIO Deutschland played an active part in the SPD parliamentary group's specialist forum on the industrial health economy, to which Verena Hubertz, Member of the Bundestag, and Gabriele Katzmarek, Member of the Bundestag, had invited. After contributions from the parliamentary group leader Rolf Mützenich, Member of the Bundestag, and Federal Health Minister Karl Lauterbach (MdB), the association's managing director Viola Bronsema discussed with representatives of the trade union Industriegewerkschaft IGBCE and of Roche and Sanofi-Aventis Germany. Bronsema emphasized that the industrial health economy is a complex ecosystem of a wide variety of companies, from medical technology to pharmaceuticals, from academic institutions, start-ups and investment companies, from medium-sized to large corporations. This must always be kept in mind when individual framework conditions are changed. After the Federal Health Minister had praised the progress in medicine in his lecture and predicted “a golden age” for the health of us all, Bronsema emphasized in her speech: The role of the biotechnology industry could be more strongly appreciated here.
The German industrial health economy is a continuous driver of growth and a job engine for the German economy. The industry is investing billions in Germany, creating thousands of new industrial jobs, mostly in collective bargaining, that our country urgently needs in the current transformation.
The German government's pharmaceutical strategy, the Health Data Utilization Act, the Digitization Act in the healthcare sector and, most recently, the Medical Research Act are intended to help strengthen the industrial health economy as a mainstay of our economy and to better position it for the future. The industry sees a need for further improvement and, above all, demands planning security.

Go back